F
Frits van Rhee
High Impact
Professor
faculty
Internal Med, College of Medicine
82 h-index
844 pubs
26,181 cited
Research Areas
Biography and Research Information
OverviewAI-generated summary
Dr. Frits van Rhee's research focuses on the molecular underpinnings and therapeutic strategies for hematological malignancies, with a particular emphasis on multiple myeloma and Castleman's Disease. He has investigated the evolutionary pathways from smoldering myeloma to overt multiple myeloma and characterized the molecular landscape of these conditions. His work also addresses disparities in access to advanced therapies, such as CAR-T cells and bispecific antibodies, for multiple myeloma patients, and examines the role of the immune microenvironment in disease progression.
Dr. van Rhee is recognized as a world-leading expert in Castleman's Disease, contributing to the validation of international clinical definitions for its subtypes. His research extends to the safety and efficacy of novel treatments, including the risk of infections associated with bispecific antibodies in multiple myeloma and real-world studies of teclistamab in relapsed refractory disease. He has published extensively, with a significant body of work encompassing hundreds of manuscripts and abstracts. His scholarship metrics include an h-index of 82, over 844 total publications, and more than 25,885 total citations, indicating a highly cited and impactful research career.
Research Overview
Dr. Frits van Rhee received his medical degree at Erasmus University, Rotterdam, Netherlands, and his PhD at the Imperial College of Science, Medicine and Technology, University of London. He trained in internal medicine and hematology in the UK, and in bone marrow transplantation (BMT) at Oxford and the Royal Postgraduate Medical School in London. Dr. van Rhee is a professor of medicine and director of developmental and translational medicine with the Myeloma Institute for Research and Therapy at the University of Arkansas for Medical Sciences. He also holds the Charles and Clydene Scharlau Chair for Hematological Malignancies Research. Dr. van Rhee holds memberships in the International Society for Experimental Hematology, the International Society for Cellular Therapy, and the European Group for Bone and Marrow Transplantation. He serves on the editorial review boards for Annals of Hematology, Bone Marrow Transplantation, and Cytotherapy. He has written hundreds of manuscripts and abstracts, as well as presented at scientific meetings. Dr. van Rhee's current research focuses on immunotherapy for myeloma. Dr. van Rhee is also a world-leading expert in Castleman's Disease.PublicationsMake an appointment with the UAMS Myeloma Institute
Metrics
- h-index: 82
- Publications: 844
- Citations: 26,181
Selected Publications
-
Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients (2026)
-
Peripheral blood immune cell profiling and response to BCMA CAR-T cell therapy in relapsed refractory multiple myeloma (2026)
-
Elucidating the grading intricacies of idiopathic multicentric Castleman disease histopathology: a pathologist’s perspective (2025)
-
Siltuximab-mediated suppression of CRP is associated with clinical response in idiopathic multicentric castleman disease (2025)
-
MM-1225: Comparison of Short-Term Outcomes and Safety Profile Between Daratumumab-Based Quadruplet Versus Triplet Induction Regimens for Patients With Transplant-Eligible Newly Diagnosed Multiple Myeloma: Meta-Analysis of Randomized Controlled Trials (2025)
-
The efficacy of teclistamab in patients with multiple myeloma and secondary plasma cell leukemia (2025)
-
Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma (2025)
-
B-cell maturation antigen (BCMA) immunohistochemistry (IHC) staining in multiple myeloma (MM) patients with prior use of BCMA-based therapies. (2025)
-
Case Report: Teclistamab in the treatment of idiopathic immune thrombocytopenia in patients with multiple myeloma (2025)
-
Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma (2025)
-
Characterizing the heterogeneity of Castleman disease and oligocentric subtype: findings from the ACCELERATE registry (2025)
-
Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages (2024)
-
Psychological Impact in Individuals with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma (2024)
-
Deciphering the genetics and mechanisms of predisposition to multiple myeloma (2024)
-
Cereblon E3 Ligase Modulators Mezigdomide and Iberdomide in Multiple Myeloma (2024)
Grants & Funding
- Qualitative Research in Castleman's Disease: Exploring Patients' Perspectives through Interviews, Project #A2-7438 United BioSource Corporation Principal Investigator
- UARK 2006-41 A Phase 1, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 (Humanized anti-CS1 Monoclonal lgG1 antibody) in Subjects with Adva Protein Design Labs, Inc Principal Investigator
- UARK 2004-61: (AMD3100-3102) A Multicenter, Randomized, Double-blind, Placebo-controlled, Comparative Trial of AMD3100 (240 ug/kg) plus G-CSF (10 ug/k AnorMED, Inc. Principal Investigator
- No FP attached Janssen Research & Development, LLC Principal Investigator
- 2004-23: (Protocol C0328T03) A Phase I Study of a Chimeric Antibody Against Interleukin-6 (CNTO 328) Administered Biweekly as an Intravenous Infusion Centocor, Inc. Principal Investigator
- KAG 301-Phase 3 Randomized, Open-Label Clinical Trial of Tanespimycin (Kos 953) plus Bortezomib Compared to Bortezomib Alone in Patients with Multiple Genzyme Principal Investigator
- No FP attached AbbVie Inc Principal Investigator
- UARK# 2012-02 TOTAL THERAPY 5B: A PHASE II TRIAL FOR HIGH-RISK MYELOMA EVALUATING Onyx Pharmaceuticals, Inc. Principal Investigator
Collaboration Network
Top Collaborators
Maurizio Zangari
University of Arkansas for Medical Sciences
26 shared publications
In database
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
- Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states
- Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma
Showing 5 of 26 shared publications
Carolina Schinke
University of Arkansas for Medical Sciences
25 shared publications
In database
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
- Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states
- Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma
Showing 5 of 25 shared publications
Sharmilan Thanendrarajan
University of Arkansas for Medical Sciences
24 shared publications
In database
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
- Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states
- Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma
Showing 5 of 24 shared publications
Samer Al Hadidi
University of Arkansas for Medical Sciences
20 shared publications
In database
- Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
- Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma
- Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level
- Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor–T Cell Therapy for Hematological Malignant Neoplasms
Showing 5 of 20 shared publications
Cody Ashby
University of Arkansas for Medical Sciences
11 shared publications
In database
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states
- TRIP13 modulates protein deubiquitination and accelerates tumor development and progression of B cell malignancies
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Epigenomic translocation of H3K4me3 broad domains over oncogenes following hijacking of super-enhancers
Showing 5 of 11 shared publications
Meera Mohan
10 shared publications
- Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma
- Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
- Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy
- Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma
Showing 5 of 10 shared publications
Fenghuang Zhan
University of Arkansas for Medical Sciences
9 shared publications
In database
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
- Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma
- TRIP13 modulates protein deubiquitination and accelerates tumor development and progression of B cell malignancies
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
Showing 5 of 9 shared publications
Guido Tricot
Winthrop Rockefeller Foundation
9 shared publications
In database
- Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma
- TRIP13 modulates protein deubiquitination and accelerates tumor development and progression of B cell malignancies
- Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
Showing 5 of 9 shared publications
Binod Dhakal
Medical College of Wisconsin (US)
8 shared publications
- Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma
- Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy
- Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma
- Corneal toxicity with belantamab mafodotin: Multi‐institutional <scp>real‐life</scp> experience
Showing 5 of 8 shared publications
Siegfried Janz
Medical College of Wisconsin (US)
8 shared publications
- TRIP13 modulates protein deubiquitination and accelerates tumor development and progression of B cell malignancies
- The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy
- Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma
Showing 5 of 8 shared publications
John D. Shaughnessy
University of Arkansas for Medical Sciences
8 shared publications
In database
- Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
- TRIP13 modulates protein deubiquitination and accelerates tumor development and progression of B cell malignancies
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma
Showing 5 of 8 shared publications
David C. Fajgenbaum
University of Pennsylvania (US)
8 shared publications
- Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric <scp>Castleman</scp> disease
- Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease
- Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease
- CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease
- Treatment consistent with idiopathic multicentric Castleman disease guidelines is associated with improved outcomes
Showing 5 of 8 shared publications
Anikó Szabó
Medical College of Wisconsin (US)
8 shared publications
- Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma
- Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
- Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy
- Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma
Showing 5 of 8 shared publications
Bart Barlogie
University of Arkansas for Medical Sciences
7 shared publications
In database
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Development and validation of an individualized and weighted Myeloma Prognostic Score System (<scp>MPSS</scp>) in patients with newly diagnosed multiple myeloma
- Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission
Showing 5 of 7 shared publications
Anita D’Souza
Medical College of Wisconsin (US)
7 shared publications
- Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma
- Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy
- Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma
- Corneal toxicity with belantamab mafodotin: Multi‐institutional <scp>real‐life</scp> experience
Showing 5 of 7 shared publications
Similar Researchers
Based on overlapping research topics
Sharmilan Thanendrarajan
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
CAR-T cell therapy research
Monoclonal and Polyclonal Antibodies Research
Carolina Schinke
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
CAR-T cell therapy research
Monoclonal and Polyclonal Antibodies Research
Behjatolah Monzavi Karbassi
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer Immunotherapy and Biomarkers
Monoclonal and Polyclonal Antibodies Research
Bailu Peng
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer Immunotherapy and Biomarkers
CAR-T cell therapy research
Tanvi Patel
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer Immunotherapy and Biomarkers
CAR-T cell therapy research
Clyde Bailey
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer Immunotherapy and Biomarkers
CAR-T cell therapy research